Overview

Study of KRN23 in Adult Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

Status:
Active, not recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

UX023T-CL201 is an, open-label, Phase 2 study. The study will be conducted in adults aged 18 years or older with TIO or ENS whose tumor/skin lesion is inoperable to assess the efficacy and safety of KRN23 administered via subcutaneous injections monthly (every 4 weeks) for a total of 144 weeks. Subjects will need to discontinue oral phosphate and vitamin D metabolite therapy prior to randomization and throughout the duration of the study.

Phase:

Phase 2

Details

Lead Sponsor:

Ultragenyx Pharmaceutical Inc

Collaborator:

Kyowa Hakko Kirin Korea Co., Ltd.